BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

Ocular

Nonclinical analysis of the hyperthermic effect of SJP-0132

March 19, 2025
Researchers from Senju Pharmaceutical Co. Ltd. presented results from preclinical studies that assessed the hyperthermic effects of SJP-0132, a selective antagonist of transient receptor potential vanilloid 1 (TRPV1), which is currently awaiting approval in Japan as an ophthalmic treatment to alleviate the signs and symptoms of dry eye disease.
Read More
Dermatologic

TCR-Nck modulation holds promise in autoimmune skin disorders

March 18, 2025
In atopic dermatitis, psoriasis and other dermatologic diseases, T cells lose tolerance to self-antigens, triggering the autoimmune response that leads to abnormal skin cell proliferation and inflammation. The use of Nck modulators may help correct dysregulated T-cell receptor (TCR) signaling, potentially restoring immune tolerance and reducing subsequent inflammatory responses.
Read More
Red coronavirus with long shadow
Infection

Long COVID science is progressing, though therapies have not yet followed

March 18, 2025
By Anette Breindl
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.
Read More
Coronavirus variants
Infection

ALG-097558 confirmed as an effective pan-coronavirus strategy

March 17, 2025
Although safe and effective vaccines for SARS-CoV-2 have been successfully developed, there are currently no therapeutic approaches available for treating acute infection, particularly for individuals at high risk of severe disease progression, and for preparedness against a potential new coronavirus pandemic.
Read More
Cancer

Combining KAT6A/B inhibitor and retinoic acid shows efficacy in neuroblastoma models

March 17, 2025
Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or immunotherapy with anti-GD2 antibodies, all with severe side effects and long-term toxicity. Retinoic acid (RA) has been shown to promote neuroblastoma growth inhibition while suppressing MYCN oncogene expression. However, its effect is reversible, and tumor regrowth may occur.
Read More
Dermatologic

APG-777 plus APG-990 combination results in superior suppression of inflammatory cytokines

March 14, 2025
APG-777 is an anti-IL-13 humanized monoclonal antibody (mAb) designed to block Th2 inflammatory signaling mediated by the IL-13Rα1/IL-4Rα complex, while APG-990 is a fully human anti-OX40L mAb that that blocks type 1/2/3 inflammatory signaling. Apogee Therapeutics Inc. is studying the combination effects of APG-777 and APG-990 as potential therapy for atopic dermatitis (AD).
Read More
Arthritis pain illustration
Immune

ORKA-002: potential best-in-class anti-IL-17A/F monoclonal antibody with extended half-life

March 14, 2025
Patients with psoriatic arthritis exhibit high levels of both IL-17A and IL-17F cytokines in the synovium. Bimekizumab, a biologic that targets both IL-17A and IL-17F, was recently approved for the treatment of plaque psoriasis and psoriatic arthritis.
Read More
Cancer

cGAS inhibition suppresses tumor growth and sensitizes DLBCL cell lines to ferroptosis

March 14, 2025
Researchers from Soochow University and affiliated organizations presented data from a study that aimed to investigate the role of cyclic GMP-AMP synthase (cGAS) in tumorigenesis and tumor progression.
Read More
Illustration of magnifying glass inspecting brain
HIV/AIDS

In HIV, draining the reservoir means understanding the brain

March 14, 2025
By Anette Breindl
The availability of effective antiretroviral therapy has lowered the risk, and the severity, of neural sequelae of HIV infection. “Early in the HIV pandemic, approximately 15% of people with HIV had dementia and or encephalitis,” Howard Fox told his audience. “Fortunately, with treatment, the prevalence of these severe disorders has been greatly lowered. But there is persistence of what are called more minor disorders – which are not minor if you have them.”
Read More
Red coronavirus with long shadow
Infection

Long COVID science is progressing, though therapies have not yet followed

March 14, 2025
By Anette Breindl
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.
Read More
Previous 1 2 … 55 56 57 58 59 60 61 62 63 … 3181 3182 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing